3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pancreatic Neoplasms
90
Breast Neoplasms
87
Carcinoma, Non-Small-Cell Lung
33
Triple Negative Breast Neoplasms
22
Squamous Cell Carcinoma of Head and Neck
19
Neoplasms
18
Neoplasm Metastasis
18
Ovarian Neoplasms
17
Stomach Neoplasms
15
Lung Neoplasms
13
Head and Neck Neoplasms
11
Esophageal Squamous Cell Carcinoma
10
Esophageal Neoplasms
10
Cholangiocarcinoma
10
Recurrence
9
Melanoma
8
Small Cell Lung Carcinoma
7
Sarcoma
7
Pancreatic Adenocarcinoma
7
Inflammatory Breast Neoplasms
7
Breast Neoplasms, Male
7
Adenocarcinoma
7
Prostatic Neoplasms
6
Fallopian Tube Neoplasms
6
Urinary Bladder Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Biliary Tract Neoplasms
5
Uterine Cervical Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Ductal, Breast
4
Interventions
Fulvestrant
6
olaparib
4
Letrozole
4
trastuzumab deruxtecan
3
Aromatase Inhibitors
3
Anastrozole
3
sacituzumab govitecan
2
pyrotinib
2
eribulin
2
dalpiciclib
2
Paclitaxel
2
Goserelin
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Capecitabine
2
toripalimab
1
talazoparib
1
sonidegib
1
ribociclib
1
pembrolizumab
1
neratinib
1
liposomal doxorubicin
1
elacestrant
1
disitamab vedotin
1
ceralasertib
1
capivasertib
1
balixafortide
1
apatinib
1
abemaciclib
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Breast Cancer
×
Albumin-Bound Paclitaxel
×
Clear all
NCT04826016
2023-03-20
POLTER
MedSIR
Phase 1/2
Withdrawn